All fields are required.

Close Appointment form

Adrenal Cortical Carcinoma (ACC) Assay

AltaBioscience provides an analytical service for the quantification and profiling of urinary steroid metabolites as biomarkers of Adrenal Cortical Carcinoma (ACC) using gas chromatography-mass spectrometry, GC-MS. The service provides the accurate quantitation of 32 urinary steroids and includes a report detailing probability of malignancy as determined by our exclusive licence on this patented computational assay.

Developed by Professor Wiebke Arlt (William Withering Chair of Medicine and Director of the Institute of Metabolism and Systems Research, IMSR, at the Centre for Endocrinology, Diabetes and Metabolism (CEDAM) University of Birmingham), this technique has significant advantages over  current diagnostic procedures, which rely on CT/MRI imaging or tissue biopsy – both of which are time-consuming and costly, and rely on indicators that can be ambiguous.

The assay is currently only available for research use only.

Our sample information page provides details of sample requirements and a sample submission form for you to download.

Our method enables a non-invasive, quick and accurate quantitation of the key steroids required to differentiate between a benign Adrenocortical Adenoma (ACA) and malignant Adrenal Cortical Carcinoma (ACC) tumour. The method can be particularly useful for the following applications:

  • Supporting diagnosis of ACC
  • Monitoring of ACA
  • Post-operative monitoring

As licensed patent holders, AltaBioscience provides a unique assay for use in assessing probaility of ACC malignancy. Other benefits include:

  • Highly sensitive and specific results – enabling targeted treatment
  • Non-invasive sampling
  • Easy sample shipping and storage
  • Cost effective diagnosis compared to imaging
  • Improved pathway for patient management
  • Easy to interpret reports
  • Fast turnaround time of results

The GC-MS assay can also be offered without the computer algorithm to be used for other diagnostic applications such as disorders of sexual development or monitoring response to steroid therapy.

  • Quantitative analysis data of all 32 steroids plus the normal reference ranges.
  • Algorithm visualisation plot showing percentage likelihood of ACA and ACC
  • Presentation of multiple samples for comparision
  • Clinical expert interpretation – provided upon request


Urine Steroid Metabolomics as a Biomarker Tool for Detecting Malignancy in Adrenal Tumors. Arlt W, Biehl M, Taylor AE, Hahner S, Libé R, Hughes BA, Schneider P, Smith DJ, Stiekema H, Krone N, Porfiri E, Opocher G, Bertherat J, Mantero F, Allolio B, Terzolo M, Nightingale P, Shackleton CH, Bertagna X, Fassnacht M, Stewart PM. J Clin Endocrinol Metab. 2011 Dec;96(12):3775-84

For more information, please email us at or call us on +44(0)121 414 5450 to speak to one of our experts.